5:00
A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCL
Laurie Sehn
3:47
Sickle cell disease: where we are now
Maria Cappellini
5:57
Making CAR T-cells happen in Europe
John Gribben
6:23
Exciting new therapy for Waldenström’s macroglobulinemia: ibrutinib plus rituximab
Meletios Dimopoulos
4:23
New CD22 CAR T-cells for pediatric R/R B-ALL are highly effective
Jing Pan
5:44
Obinutuzumab/chlorambucil gives OS benefit over rituximab in frontline CLL
Valentin Goede
4:15
Advanced Hodgkin lymphoma: AHL2011 data update from EHA 2018
Olivier Casasnovas
6:07
Big data for HemOnc in Europe: HARMONY
Jesús María Hernández Rivas
6:39
Update on bb2121 CAR T-cell product for MM from EHA 2018
Jesús Berdeja
6:38
Follicular lymphoma: is RELEVANCE relevant?
Frank Morschhauser
5:48
Iron and inflammation in anemia and sickle cell disease
Francesca Vinchi
7:11
First-in-human CLL1-CD33 compound CAR T-cells for AML
Fang Liu
3:58
ZUMA-1: a pivotal trial of CAR T-cells in NHL
Yi Lin
4:35
The use of anticoagulants in cancer-associated venous thromboembolism
Alejandro Lazo-Langner
6:30
GHSD HD18 study: reducing chemotherapy toxicity in advanced stage Hodgkin lymphoma
Peter Borchmann
4:38
Different is better: the fight against leukemia
Michaela Kotrová
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals